Sterile manufacturing specialist SCM Pharma is set to expand its vial filling capability after winning several clinical trials and commercial supply contracts.
The UK-based contract development and manufacturing organisation (CDMO) has invested more than £500,000 in new vial filling equipment that will arrive this summer and command a dedicated suite at its facility.
SCM Pharma undertakes vial filling across many projects and the new automated filler will deliver increased capacity, efficiency and integrate with its containment isolator. The move follows increased demand for liquid and powder filling from new and existing clients with scale-up requirements.
Neal Wesley, technical director at SCM Pharma, said: ‘The new kit will give us a true containment system for vial filling in that it will allow us to fill various types of potent materials in different sized vials while being totally safe for the product and operator.
‘By having a system that isn’t compromised in any way, we are able to handle more cytotoxic products such as oncology drugs, which we can safely fill at speed into vials under aseptic conditions to meet the demands of our clients.’
Although the investment will be a step change in SCM’s current filling capabilities, it remains at a scale that will be of interest mainly to companies requiring products for clinical trials and the supply of licensed drugs needed in niche markets such as orphan drugs.
SCM Pharma expands vial filling capability
Invests more than £500,000 in equipment to be installed in the summer
You may also like
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
HAPI capacity reaches an all-time high
While today’s drugs are more targeted and effective, they bring with them production issues of sterility and higher potency. Susan Birks reports on how the contract manufacturing market has responded to the growing demand for specialist high potency and sterile services
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
The changing landscape of clinical trial manufacturing
With regulation changes, the death of the blockbuster, focus on personalised medicines and less R&D spend than ever before, the clinical trial manufacturing landscape has undergone many changes. SCM Pharma’s Dianne Sharp reviews the sector and outlines what companies of the future could look like